Accuracy of controlled attenuation parameter measurement for the detection of steatosis in autoimmune liver diseases.
Autoimmune hepatitis
Autoimmune liver disease
Controlled attenuation parameter
Inflammation
Non-invasive steatosis measurement
Primary biliary cholangitis
Primary sclerosing cholangitis
Steatosis hepatis
Journal
JHEP reports : innovation in hepatology
ISSN: 2589-5559
Titre abrégé: JHEP Rep
Pays: Netherlands
ID NLM: 101761237
Informations de publication
Date de publication:
Dec 2023
Dec 2023
Historique:
received:
12
02
2023
revised:
08
08
2023
accepted:
17
08
2023
medline:
13
11
2023
pubmed:
13
11
2023
entrez:
13
11
2023
Statut:
epublish
Résumé
Concurrent fatty liver disease represents an emerging challenge in the care of individuals with autoimmune liver diseases (AILD). Therefore, we aimed to validate the ultrasound-based method of controlled-attenuation parameter (CAP) as a non-invasive tool to detect hepatic steatosis in individuals with AILD. The diagnostic performance of CAP to determine biopsy-proven hepatic steatosis (>5%) was assessed in individuals with AILD (autoimmune hepatitis [AIH], primary biliary cholangitis [PBC], primary biliary cholangitis [PSC], or variant syndromes) who underwent liver biopsy at the University Medical Center Hamburg-Eppendorf between 2015-2020 by calculating the area under the receiver operating characteristic (AUROC) curves. In AIH, the impact of disease activity was evaluated by assessment of CAP upon resolution of hepatic inflammation during follow-up. Overall, 433 individuals with AILD (AIH: 218, PBC: 51, PSC: 85, PBC/AIH: 63, PSC/AIH: 16) were included. Histologically proven steatosis was present in 90 individuals (20.8%). Steatosis was less frequently observed in people with PSC (14%) than in other AILD. CAP values correlated positively with grade of steatosis ( In PBC and PSC, hepatic steatosis can be reliably detected by applying disease-specific thresholds of CAP. In AIH, the diagnostic accuracy of CAP is moderate at diagnosis, but improves after acute hepatitis has resolved. Non-invasive estimation of fat content in the liver can be performed with the ultrasound-based method of controlled-attenuation parameter (CAP). Here, we showed that the presence of a concomitant fatty liver is frequent in people with autoimmune liver diseases and we determined disease-specific thresholds of CAP to best predict the presence of a fatty liver. CAP measurement was shown to be a valid tool to detect fatty liver in individuals with PSC and PBC; however, in AIH, CAP had limited accuracy especially when significant inflammatory activity was present in the liver. In the context of substantial liver inflammation, therefore, CAP values should be interpreted with caution, and measurements should be repeated after acute hepatitis has resolved.
Sections du résumé
Background & Aims
UNASSIGNED
Concurrent fatty liver disease represents an emerging challenge in the care of individuals with autoimmune liver diseases (AILD). Therefore, we aimed to validate the ultrasound-based method of controlled-attenuation parameter (CAP) as a non-invasive tool to detect hepatic steatosis in individuals with AILD.
Methods
UNASSIGNED
The diagnostic performance of CAP to determine biopsy-proven hepatic steatosis (>5%) was assessed in individuals with AILD (autoimmune hepatitis [AIH], primary biliary cholangitis [PBC], primary biliary cholangitis [PSC], or variant syndromes) who underwent liver biopsy at the University Medical Center Hamburg-Eppendorf between 2015-2020 by calculating the area under the receiver operating characteristic (AUROC) curves. In AIH, the impact of disease activity was evaluated by assessment of CAP upon resolution of hepatic inflammation during follow-up.
Results
UNASSIGNED
Overall, 433 individuals with AILD (AIH: 218, PBC: 51, PSC: 85, PBC/AIH: 63, PSC/AIH: 16) were included. Histologically proven steatosis was present in 90 individuals (20.8%). Steatosis was less frequently observed in people with PSC (14%) than in other AILD. CAP values correlated positively with grade of steatosis (
Conclusions
UNASSIGNED
In PBC and PSC, hepatic steatosis can be reliably detected by applying disease-specific thresholds of CAP. In AIH, the diagnostic accuracy of CAP is moderate at diagnosis, but improves after acute hepatitis has resolved.
Impact and implications
UNASSIGNED
Non-invasive estimation of fat content in the liver can be performed with the ultrasound-based method of controlled-attenuation parameter (CAP). Here, we showed that the presence of a concomitant fatty liver is frequent in people with autoimmune liver diseases and we determined disease-specific thresholds of CAP to best predict the presence of a fatty liver. CAP measurement was shown to be a valid tool to detect fatty liver in individuals with PSC and PBC; however, in AIH, CAP had limited accuracy especially when significant inflammatory activity was present in the liver. In the context of substantial liver inflammation, therefore, CAP values should be interpreted with caution, and measurements should be repeated after acute hepatitis has resolved.
Identifiants
pubmed: 37954487
doi: 10.1016/j.jhepr.2023.100898
pii: S2589-5559(23)00229-X
pmc: PMC10632533
doi:
Types de publication
Journal Article
Langues
eng
Pagination
100898Informations de copyright
© 2023 The Authors.
Déclaration de conflit d'intérêts
The authors declare no conflicts of interest related to this manuscript. Please refer to the accompanying ICMJE disclosure forms for further details.
Références
Dig Dis Sci. 2014 Jul;59(7):1645-6
pubmed: 24510391
Hepatology. 2005 Jun;41(6):1313-21
pubmed: 15915461
J Steroid Biochem Mol Biol. 2015 Nov;154:94-103
pubmed: 26241028
J Hepatol. 1995 Jun;22(6):696-9
pubmed: 7560864
Liver Int. 2020 May;40(5):1151-1158
pubmed: 31823449
J Hepatol. 2015 Oct;63(4):971-1004
pubmed: 26341719
J Gastroenterol Hepatol. 2013 Jul;28(7):1194-201
pubmed: 23425053
Dig Dis Sci. 2016 Sep;61(9):2710-20
pubmed: 27262844
Am J Surg Pathol. 1995 Dec;19(12):1409-17
pubmed: 7503362
Nat Rev Gastroenterol Hepatol. 2022 Jan;19(1):60-78
pubmed: 34707258
EClinicalMedicine. 2022 Jul 10;51:101547
pubmed: 35844772
United European Gastroenterol J. 2020 Apr;8(3):321-331
pubmed: 32213023
Dig Dis Sci. 2021 Apr;66(4):1297-1305
pubmed: 32337667
Dig Dis Sci. 2016 Sep;61(9):2462-4
pubmed: 27468739
J Hepatol. 2016 Oct;65(4):769-775
pubmed: 27238753
Clin Gastroenterol Hepatol. 2015 Apr;13(4):643-54.e1-9; quiz e39-40
pubmed: 24768810
J Hepatol. 2022 Apr;76(4):841-849
pubmed: 35066089
Liver Int. 2012 Jul;32(6):902-10
pubmed: 22435761
JHEP Rep. 2021 Jun 12;3(4):100321
pubmed: 34381983
Clin Liver Dis. 2018 Feb;22(1):11-21
pubmed: 29128051
JGH Open. 2018 Mar 30;2(2):54-58
pubmed: 30483564
J Hepatol. 2022 Sep;77(3):761-806
pubmed: 35738507
Hum Pathol. 2017 Nov;69:55-62
pubmed: 28970141
Gastroenterology. 2018 Dec;155(6):1828-1837.e2
pubmed: 30144434
Hepatology. 2016 Jul;64(1):73-84
pubmed: 26707365
J Hepatol. 2017 Jul;67(1):145-172
pubmed: 28427765
J Hepatol. 2016 Jun;64(6):1388-402
pubmed: 27062661
Radiology. 1982 Apr;143(1):29-36
pubmed: 7063747
Psychometrika. 1947 Jun;12(2):153-7
pubmed: 20254758
Eur J Intern Med. 2020 May;75:1-9
pubmed: 32051092
Endoscopy. 2003 Jan;35(1):55-60
pubmed: 12510227
World J Gastroenterol. 2021 Jan 7;27(1):80-91
pubmed: 33505152
Clin Liver Dis (Hoboken). 2021 Feb 01;17(1):23-28
pubmed: 33552482
Medicine (Baltimore). 2020 Oct 16;99(42):e22805
pubmed: 33080756
J Gastroenterol. 2017 May;52(5):631-640
pubmed: 27722997
J Hepatol. 2017 Sep;67(3):577-584
pubmed: 28506907
BMC Gastroenterol. 2019 Apr 8;19(1):51
pubmed: 30961539
Gastroenterology. 2005 Jun;128(7):1898-906
pubmed: 15940625
Aliment Pharmacol Ther. 2018 Nov;48(9):951-960
pubmed: 30226274
Diabetes Metab Syndr Obes. 2020 Apr 16;13:1133-1145
pubmed: 32368109
Ultrasound Med Biol. 2010 Nov;36(11):1825-35
pubmed: 20870345